Prognostic Impact of a Monosomal Karyotype in Patients With Acute Myeloid Leukemia Undergoing Allogeneic Stem Cell Transplantation  by Hemmati, P.G. et al.
S248 Poster Session Icyclophosphamide 100mg/kg [ideal bw] day -3. Radiation was
started at 1200cGy delivered in 150cGy fractions twice a day.
Dose of radiation was escalated in increments of 150cGy using co-
horts of 3 patients until dose limiting toxicity was reached according
to Bearman grading scale. All patients received peripheral stem cells
on day 0. GVHD prophylaxis consists of tacrolimus and sirolimus.
Patient characteristics are as follows: age 33 yrs(20-54); AML 5,
ALL 5, Biphenotypic 2; Disease stage IF 7, 1 RL 5; Donor source
sibling 8, matched unrelated 1, mismatched (1 allele) unrelated do-
nor 3;WBC atHCT1.4(0.2-100.0), blasts in blood 18(0-77%), mar-
row blasts 30(0-95%). Two patients with no marrow blasts had
persistent extramedullary disease at HCT. With a median follow-
up for alive patients of 9.2 months (2.9- 27) the overall survival
and cumulative incidence of relapse at 6 months are 63% (CI 41%;
78%) and 17% (CI 4%; 50%), respectively. Six patients were treated
at 1500cGy without reaching DLT. Four (33%) patients developed
acute GVHD, 1 (8%) developed Grade 3-4. The day 30 and day 100
NRM was 0% and 8%, respectively. Most common toxicity was
grade 2 stomatitis Causes of death were disease progression 3,
GVHD 2 and infection 1.
These preliminary results suggest that 1.) doses of targeted mar-
row radiation delivered by Tomotherapy can be safely escalated to
1500cGy in combination with etoposide and cyclophosphamide
(DLT not reached); and that 2.) a reduction in relapse/progression
can be achieved without increasing NRM in this high risk patient
population. This observation needs to be confirmed in a larger group
of patients.257
EFFECT OF CHROMOSOMAL LESIONS DETECTED BY SNP-ARRAY KARYO-
TYPING ON SURVIVAL AFTER ALLOGENEIC HCT FOR MDS AND AML
Mohan, S.R., Tiu, R.V., Gondek, L.P., O’Keefe, C.L., Kalaycio, M.,
Sobecks, R.M., Copelan, E.A., Maciejewski, J.P. Cleveland Clinic, Cleve-
land, OH
The prognostic value of chromosomal abnormalities identified by
metaphase cytogenetics (MC) in MDS/AML is well-established and
has been incorporated into risk stratification schemes. High density
single nucleotide polymorphism array (SNP-A) is a karyotyping tool
complementary to MC that can detect previously cryptic chromo-
somal lesions, including acquired somatic uniparental disomy
(UPD). We retrospectively analyzed SNP-A results to assess the
prognostic relevance of chromosomal abnormalities detected by
this method in MDS/AML patients (pts) undergoing allogeneic he-
matopoietic cell transplantation (HCT).
38 pts who underwent allogeneic HCT between 2004 and 2009
had pre-HCTblood ormarrow samples available for SNP-A testing.
Cytogenetic analysis was performed on marrow aspirate by standard
metaphase karyotypingmethods.We performed 250K and 6.0 SNP-
A analyses and correlated the results with clinical outcomes. Median
pt age at HCT was 56 years (range 20-70). The indication for HCT
was either MDS (n 5 25, 66%) or AML arising from MDS, and
HCT was performed at a median of 5 months from diagnosis (range
3-41). Donor sources were HLA-identical related (21, 55%), unre-
lated (13, 34%), and cord blood (4, 11%); myeloablative busulfan-
based conditioning regimens were used for 24 pts (62%) and reduced
intensity fludarabine-based conditioning for the remainder.
Unbalanced chromosomal lesions were detected in 45% of pts by
MC and 71% by SNP-A. Acquired somatic UPD, not detectable by
MC,was identified in 26%of pts. The presence of SNP-A abnormal-
ities was associated with a trend toward worse overall survival (OS)
(16 months vs 45, p 5 .11). The group of pts\ 60 years of age dis-
played significantly worseOSwhen SNP-A abnormalities were iden-
tified (7 months vs not reached, p5 .024). HCT patients with UPD
exhibited worse OS (8.8 months vs not reached, p 5 .016) and re-
lapse-free survival (RFS) (6.6 vs 17.6, p 5 .018) than those without
such lesions. None of the other factors analyzed including the num-
ber of prior therapies, HCT donor source, conditioning regimen, or
time from diagnosis to HCT was associated with OS or RFS in uni-
variate analyses. We conclude that the detection of new SNP-A ab-
normalities, particularly UPD, may provide important prognostic
information in pts with MDS/AML undergoing HCT and should
be further investigated.258
METALLOPORYPHYRIN CONTROLS THE DIFFERENTIATION OF HUMAN
PROMYELOCYTIC LEUKEMIC CELLS
Park, J.1, Noh, E.-M.2, Lee, Y.-R.2, Lee, E.-K.2, Hong, J.H.1, Lee, J.H.1,
Kim, J.-S.2 1Gachon University of Medicine and Science, Gil Hospital,
Incheon, Korea; 2 Institute for Medical Sciences, Chonbuk National
University Medical School, Jeonju, Korea
Backgroud:Heme oxygenase -1 (HO-1) is an inducible cytoprotec-
tivemolecule, which displays antioxidant, anti-apoptotic and anti-in-
flammatory effects. HO-1 is well induced in leukemia. However,
there is no report about role of HO-1 in leukemia.
Aims:We investigated the involvement of HO-1 in the differentia-
tion of HL-60 cells.
Methods:HO-1 expression was measured by western blot and real-
time PCR.Differentiation ofHL-60 cells was determined byCD11b
expression through flow cytometric analysis.
Results: Dimethylsulfoxide (DMSO), a representative differentia-
tion inducer of HL-60 cells, induced completely decrease HO-1 ex-
pression in a time-dependent manner, but increase CD11b,
indicating that HO-1 might have negative function in DMSO-in-
duced differentiation of HL-60 cells. Zinc protoporphyrin (ZnPP),
a strong inhibitor of HO-1, induced differentiation of HL-60 cells,
as evidenced by a marked increase in the expression of CD11b fol-
lowing ZnPP treatment. In contrast, treatment with cobalt proto-
porphyrin (CoPP), an activator of HO-1, decreased CD11b
expression. ZnPP induced down-regulation ofHO-1 protein expres-
sion in HL-60 cells, while CoPP induced up-regulation. In addition,
ZnPP treatment caused a decrease in pRb and cyclin D1 expression
and an increase in p21 and p27 expression.
Conclusions: These results suggest that down-regulation of HO-1
might be necessary for DMSO-induced HL-60 differentiation. This
study provides the first evidence that HO-1 plays an important role
in DMSO-induced differentiation of HL-60 cells.259
PROGNOSTIC IMPACT OF A MONOSOMAL KARYOTYPE IN PATIENTS
WITH ACUTE MYELOID LEUKEMIA UNDERGOING ALLOGENEIC STEM
CELL TRANSPLANTATION
Hemmati, P.G.1, Terwey, T.H.1, le Coutre, P.1, Stieler, J.1,
Vuong, L.G.1, Massenkeil, G.2, Doerken, B.1, Arnold, R.1 1Charite -
Universitaetsmedizin Berlin, Berlin, Germany; 2City Hospital
Guetersloh, Guetersloh, Germany
Purpose: Allogeneic stem cell transplantation (alloSCT) is a highly
effective treatment for patients (pts) with acute myeloid leukemia
(AML). Recently, the presence of a monosomal karyotype was shown
to confer to a highly unfavorable prognosis in pts with AML treated
with conventional chemotherapy. Therefore, we investigated the
prognostic impact of a monosomal karyotype on the outcome of
pts with AML following alloSCT.
Patients and Methods: We retrospectively analyzed 153 pts with
AML (median age: 45 years, range: 17 – 68 years) who underwent al-
loSCT in complete remission (CR) at our center between 1994 and
2008. 92 pts (82%) had de novo AML, 27 pts (18%) had therapy-re-
lated AML (tAML) or AML evolving from myelodysplastic syn-
drome. As a stem cell source 131 pts (86%) received peripheral
blood stem cells (PBSCs), 22 pts (14%) received bone marrow
(BM). Conditioning consisted of standard myeloablative condition-
ing (MAC) (12 Gy TBI, 2x60mg/kg cyclophosphamide) in 90 pts
(59%). 63 pts (41%) received reduced intensity conditioning (RIC)
(2x4mg busulfan, 6x30 mg/m2 fludarabine, 4x10mg/kg ATG). 10
pts (7%) had a core-binding factor leukemia (CBF group), 64 pts
(41%) were cytogenetically normal (CN group), 19 pts (12%) had
an unfavorable risk MK-negative karyotype (MK- group) and 19
pts (12%) had a highly unfavorable MK-positive karyotype (MK1
group) (Breems et al., JCO 26: 4791-4797).
Results: After a median follow-up of 58 months (range: 13-176
months) for the surviving pts, 86 pts (56%) are alive and in CR.
Causes of death were relapse in 33 pts (22%) or infections/GvHD
in 32 pts (22%). At 3 years projectedOS was 55%, whereas the prob-
ability of relapse or non-relapse mortality (NRM) was 32% or 22%
for the whole cohort. At 3 years patients in theMK1 group had a sta-
tistically significantly lower overall survival (OS) of 25% as opposed
to 49% (MK- group), 66% (CN group), or 67% (CBF-group)
Poster Session I S249(p 5 0.01). Likewise, the probability or relapse was highest in the
MK1 group (72%) as compared to the MK- group (37%), the CN
group (24%), or the CBF group (14%) (p 5 0.001). There was no
statistically significant difference in non-relapse mortality between
the four groups.
Conclusions:Our results indicate that cytogenetics is still one of the
most important prognostic factors. In particular, the presence of
a monosomal karyotype provides a strong negative prognostic pre-
diction for patients with AML undergoing alloSCT. These patients
should be referred to alloSCT in early in CR1.260
SYNERGISTIC CYTOTOXICITY OF BUSULFAN AND NUCLEOSIDE ANALOGS
IN HUMAN LYMPHOID CELL LINES
Valdez, B.C.1, Wang, G.1, Li, Y.1, Murray, D.2, Champlin, R.E.1,
Andersson, B.S.1 1UTMDAnderson Cancer Center, Houston, TX; 2Cross
Cancer Institute, Edmonton, AB, Canada
Lymphoid leukemia and Non-Hodgkin’s lymphoma (NHL) are
heterogeneous diseases, which require various treatment modalities.
Although the success of hematopoietic stem cell transplantation
(HSCT) for myeloid leukemia has been well documented in the
last decade, advances in lymphoid malignancies have been modest
and the efficacy of HSCT for these diseases merits further study.
To identify potential efficacious pretransplant conditioning therapy
for these diseases, we performed in vitro cellular studies on the pos-
sible synergistic cytotoxicity of the DNA-alkylating agent busulfan
(Bu) and nucleoside analogs (NA) clofarabine (Clo), fludarabine
(Flu) and gemcitabine (Gem). Daudi (B cell lymphoblast), J45.01
(T cell lymphoblast) and U937 (monocytic/lymphoblast) cells were
exposed to these drugs, either individually or in combinations, and
analyzed for cell survival by the MTT assay and for protein level
and modifications by Western blot analysis. The three cell lines ex-
hibited different drug sensitivities as suggested by the IC50 values:
Daudi – 40 mM Bu, 80 nM Clo, 30 mM Flu and 2 nM Gem; J45.01
– 100 mM Bu, 60 nM Clo, 0.8 mM Flu and 25 nM Gem; U937 -
160 mM Bu, 20 nM Clo, 1.2 mM Flu and 70 nM Gem. Synergistic
cytotoxicities were observed when the drugs were combined at
IC10 – IC20 concentrations with U937 cells being the most sensitive.
Exposure of cells to [Gem1Clo1Bu], [Gem1Flu1Bu] or [Clo1-
Flu1Bu] for 4 days resulted in 5%-15% survival of U937 cells,
20%-50% of Daudi cells and 45%-80% of J45.01 cells. The effects
of these drug combinations on cell survival are consistent withDNA-
damage response as indicated by the phosphorylation of H2AX,
ATM and SMC1 proteins, and cleavage of PARP-1. The observed
methylations of histone 3 may suggest chromatin remodeling which
may contribute to the pronounced activity of [NA1Bu] combina-
tions. Interestingly, [twoNA1 Bu] combinations are muchmore ef-
ficacious than [one NA1 Bu]. Exposure of Daudi, J45.01 and U937
cells to [Gem1Bu] for 4 days resulted in 85%, 100% and 78% cell
survival, respectively. Similar exposure to [Gem1Clo1Bu] resulted
in 50%, 60% and 5% survival and exposure to [Gem1Flu1Bu] re-
sulted in 20%, 80% and 6% survival of Daudi, J45.01, and U937
cells, respectively. Our results suggest that combination of two NA
with Bu may be more active than Bu plus one NA. The findings sup-
port the introduction of [twoNA1 Bu] as part of pretransplant con-
ditioning regimen for advanced, aggressive lymphoid malignancies.261
ALLOGENEIC AND AUTOLOGOUS TRANSPLANTATION FOR THE TREAT-
MENT OF ADULT ALL
Tsai, J.2, Martin, T.1, Linker, C.1, Damon, L.1 1University of California,
San Francisco, San Francisco, CA; 2CaseWestern Reserve, Cleveland, OH
Introduction: The Philadelphia chromosome translocation ([Ph1)
is the most frequent cytogenetic abnormality detected in adult ALL.
Ph1 patients are classified as high-risk, with allogeneic hematopoi-
etic stem cell transplantation (alloHCT) considered the best chance
for cure. The role of autologous transplantation (autoHCT) in the
treatment of these patients remains controversial. More recently, ty-rosine kinase inhibitors (TKIs) have shown promise in treating Ph1
ALL. The long-term outcomes with TKI’s plus chemotherapy re-
main poor, consequently transplantation is still considered standard.
AtUCSF, Ph1ALLpatients without histocompatible donors are of-
fered autoHCT. In this study we retrospectively analyzed adult ALL
patients undergoing alloHCT and autoHCT at UCSF from 1986 to
2009 to identify factors influencing outcome.
Patients and Methods: 121 patients diagnosed with ALL under-
went autoHCT or alloHCT at UCSF since 1986. 42 patients were
Ph positive; based on cytogenetic and/or molecular methods. The
mean age at transplant was 36 overall (15-64), and 43 for Ph1 pa-
tients (23-64). Patients received autoHCT or alloHCT based on do-
nor availability. Overall, 43 patients underwent autoHCT, and 78
underwent alloHCT. For the Ph1 subgroup, 13 and 29 received au-
toHCT and alloHCT respectively. Conditioning consisted of either
total body irradiation (TBI) with etoposide and/or cyclophospha-
mide; or fludarabine with busulfan. AlloHCT patients received stan-
dard GVHD prophylaxis, and all patients received ID prophylaxis.
Results: The median disease-free survival (DFS) overall was 1.59
years for patients receiving autoHCT and 1.7 years for those receiv-
ing alloHCT. The 5-year probability of DFS was 38% for au-
toHCT, and 44% for alloHCT with treatment-related mortality
of 9% and 36%, respectively. In the subset of Ph1 patients, 5-year
probability of DFS was 58% and 40%, respectively, with no signifi-
cant difference detected. Improved DFS with noted following TKI
use (70% in the autologous group, n10; 58% in the allogeneic group,
n17). Status at transplantation correlated with probability of DFS.
TBI-based regimens and age were not found to influence outcomes.
Conclusion:Our data support the use of alloHCT for the treatment
of ALL, including Ph1 patients. The data with autoHCT are en-
couraging, with impressive results found following the addition of
TKI therapy. A larger Phase II study evaluating the role of autoHCT
in PH1 ALL appears warranted.262
PURINE NUCLEOSIDE ANALOGS EXERT SYNERGISTIC CYTOTOXICITY
WITH THE DNA-ALKYLATING AGENT BUSULFAN IN HUMAN MYELOID
LEUKEMIA
Wang, G.1, Valdez, B.C.1, Li, Y.1, Murray, D.2, Champlin, R.E.1,
Andersson, B.S.1 1UTMDAnderson Cancer Center, Houston, TX; 2Cross
Cancer Institute, Edmonton, AB, Canada
The purine nucleoside analogs fludarabine (Flu) and clofarabine
(Clo) were recently shown to have synergistic cytotoxic activity
when combined with busulfan (Bu) in AML cell lines and in primary
explanted AML cells. We attributed most of this synergism to ATM
pathway activation and chromatin remodeling. We have now ex-
tended these studies to include gemcitabine (Gem), a pyrimidine nu-
cleoside analog, and determined their efficacy and synergism in
myeloid cells including two AML cell lines (KBM3/Bu2506 and
OCI-AML3) and two CML cell lines (B5/Bu2506 and KBM5).
Combination of sub-lethal (IC10 – IC20) concentrations of the re-
spective agents [Flu1Clo1Bu] was demonstrated to be synergisti-
cally cytotoxic to both AML cell lines and KBM5 but less active
against B5/Bu2506 cells. Similar results were obtained when cells
were exposed to sub-lethal concentations (IC10 – IC20) of
[Clo1Gem1Bu] and [Flu1Gem1Bu] suggesting that replacement
of either Clo or Flu with Gem in triple-drug exposure did not result
in significantly different phenotypic responses.Western blot analysis
indicates DNA-damage response as shown by the activation of ATM
and apoptotic pathways in cells exposed to triple-drug combinations.
Since chromatin remodeling is involved in the efficacy of [Clo1
Flu1Bu] in AML cells, we hypothesize that similar mechanism is in-
volved in the efficacy of [Clo1Gem1Bu] and [Flu1Gem1Bu]. Al-
though limited in sample size, our present and published studies
suggest that combination of Bu with two nucleoside analogs as
part of pretransplant therapy will be more efficacious against
AML. However, the relative resistance of B5/Bu2506 cells and sensi-
tivity of KBM5 cells to triple-drug combinations suggests varied re-
sponses of CML cells. Further experiments using additional CML
cell lines and primary explanted CML cells are warranted to define
the relevance of [nucleoside analogs1Bu] combinations in pretrans-
plant regimen for CML patients who will undergo hematopoietic
